The fastest way to sabotage your own submission?
Set impurity limits to “look safe”
- Regulatory pushes for tighter limits – because “lower is safer”
- R&D pushes for wider limits – because that’s “safe, given how products behave over time”
Both sides think they’re protecting the product. Sometimes both are wrong!
Here’s what actually happens:
Set the limit too tight – based on early data:
- You risk ‘surprise’ elevated impurity levels at 12 – 18 months
- That once ‘unspecified impurity’ now needs to be ‘specified’
- That brings you to discussing impurity standards and partial/ re-validations
What started as a ‘conservative’ decision now stretches your development timeline.
Set the limit too wide – based purely on batch data:
- Open invitation to deficiencies: reviewer asks how this aligns with qualification logic
- Questions on qualification logic
- Pressure to justify why the spec wasn’t aligned to safety thresholds
What looked like a ‘minor limit adjustment’ becomes a high-pressure technical exercise- often in the middle of a deficiency cycle.
Worse, if development batches only passed under wide limits, tightening later may reveal the product doesn’t comply.
And now you’re no longer debating limits. You’re debating:
- Reformulation
- Submission withdrawal
- Commercial risk
All because the original limit was built around batch data alone.
The limit has to be justifiable from two perspectives:
- Patient exposure (safety/ qualification) and
- Realistic worst-case growth over shelf-life, within what your method can measure and control.
Before finalizing an impurity specs, stress-test five things:
- Qualification logic
- Trajectory
- Control strategy
- Method capability
- Lifecycle reality
Impurity limits are not stats. They are strategic decisions with clinical and commercial consequences. And that’s why they’re rarely a “minor adjustment”.
Related: Pharmaceutical Impurities Calculator
Resource Person: Pearl Pereira Nambiar